This is the web version of Brainstorm Health Daily, Coins2Day’s daily newsletter on the top health care news. To get it delivered daily to your in-box, sign up here.
The Food and Drug Administration (FDA) on Thursday approved BeiGene’s Brukinsa, a treatment for the rare blood cancer mantle cell lymphoma (MCL). The immunotherapy drug is approved for adult patients who have been treated with at least one other medicine.
From a business perspective, it’s big news for BeiGene—the China-based biotech that’s one of the pioneers in that country’s biopharma Renaissance. New stock exchange rules in Hong Kong have helped fledgling biotechs in China raise capital; BeiGene, for its part, had a nearly $160 million U.S. Public offering in 2016 and then a $903 million secondary Hong Kong IPO in 2018.
American companies have taken notice. In October, Amgen took a 20.5% stake in BeiGene. It may be feeling good about that bet right about now.
Read on for the day’s news.
Sy Mukherjee
[email protected]
@the_sy_guy
DIGITAL HEALTH
A whistleblower's account of the Google-Ascension partnership. We'll be delving into this issue in far greater detail in the coming weeks and months—but it's worth noting, for now at least, the striking piece published in the Guardian from an individual who claims to be a whistleblower on Google's efforts to collect personal health data in conjunction with a major U.S. Medical provider (dubbed "Project Nightingale". ) (The Guardian)
Apple will allow users to enroll in three health studies. On a related note in the medical data collection industry... Apple launched a new app in conjunction with the Harvard T.H. Chan School of Public Health and the NIH’s National Institute of Environmental Health Sciences that will allow Apple Watch and iPhone users to participate in three separate public health studies. The organizations say that users will be able to control what data is shared, but the available options would include the Apple Women’s Health Study, Apple Heart and Movement Study, and the Apple Hearing Study. (Reuters)
INDICATIONS
Amarin snags a critical FDA committee recommendation for its fish oil drug. An expert advisory panel to the Food and Drug Administration (FDA) on Thursday unanimously recommended expanding the label for Amarin's fish oil-based treatment Vascepa—and the recommendation, if ratified by the broader agency, could prove a massive financial boon to Amarin. The FDA panel is, in essence, ratifying Amarin's phase 3 clinical trial data showing 25% relative reductions in major cardiovascular events like stroke and heart attack in at-risk patients. (BioPharma Dive)
REQUIRED READING
The Stock Market Has Hit 19 New Highs in 2019 Alone. Why?By Ben Carlson
Can Goldman Sachs CEO David Solomon Get the Storied Bank to Grow Again?, by Jen Wieczner
Is Design That Important?By Clay Chandler
How the Best Workplaces Are Winning Over Employees With Parental Benefits, by Ed Frauenheim
Sign up for other Coins2Day newsletters.
IF YOU LIKE THIS EMAIL...
Share today’s Brainstorm Health with a friend.
Did someone share this with you?Sign up here. For previous editions, click here.
For even more, check out raceAhead, Coins2Day's daily newsletter on culture in corporate America. Sign up here.